ImmunoLink Therapies

ImmunoLink is a preclinical-stage biotechnology company focused on developing a novel class of protein-polymer conjugates to treat autoimmune diseases. The company's proprietary ImmunoLink platform enables the creation of site-specific, multivalent protein-polymer hybrids that significantly extend the half-life and enhance the therapeutic window of immunomodulators. By leveraging this technology, ImmunoLink aims to develop "inverse vaccines" that can selectively suppress pathogenic immune responses without causing systemic immunosuppression. Their lead programs are currently targeting Type 1 diabetes and multiple sclerosis through the targeted delivery of checkpoint agonists.